How new safety evidence is boosting India’s expanding Ashwagandha market
Government-backed 24-week trial of 1,200 adults finds no liver or kidney injury from a standardised root extract.
Attribution
This digest is published with acknowledgment to Business Today. For the complete analysis, headnotes, and citations, please refer to the source.
Read on Business Today